Wall Street expects a year-over-year decline in earnings on higher revenues when Intellia Therapeutics, Inc. (NTLA) reports results for the quarter ended December 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be release ...

CAMBRIDGE, Mass. & MENLO PARK, Calif.--(BUSINESS WIRE)--Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, and ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis (CF). CF is a genetic di ...

公司业绩 - Intellia Therapeutics是一家领先的临床阶段基因编辑公司，专注于用CRISPR技术革新医学[1] - 公司将于2024年2月22日上午8点举行第四季度和全年2023年财务业绩和运营亮点电话会议[1] - Intellia的in vivo项目利用CRISPR技术在人体内精确编辑致病基因，而ex vivo项目则利用CRISPR技术在体外工程人类细胞治疗癌症和自身免疫疾病[4] 电话会议信息 - 参与电话会议的美国拨打者应拨打1-833-316-0545，国际拨打者应拨打1-412-317-5726[2] - 电话会议重播将于2024年2月22日中午12点开始在Intellia网站的投资者和媒体页面提供[3] 技术发展 - 公司不断扩展CRISPR平台的能力，以利用基因编辑的全部潜力，推动新型药物的发展[5]

CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2023 financial results and operational highlights in a conference call on February 22, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the cal ...

NTLA-2002疗效 - NTLA-2002单剂量可显著减少HAE发作率，9名患者在16周观察期后仍完全无发作[1] - NTLA-2002在所有剂量水平下耐受性良好[1] NTLA-2002研究计划 - Intellia计划在2024年下半年启动NTLA-2002的全球关键性第三阶段研究[4]

A downtrend has been apparent in Intellia Therapeutics, Inc. (NTLA) lately with too much selling pressure. The stock has declined 19.1% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical in ...

公司业务 - Intellia Therapeutics正在开发NTLA-2001用于治疗转甲状蛋白淀粉样变性疾病，这是一种由危险蛋白质积聚引起的疾病[2] - 公司还有其他几个候选药物在研发中，包括NTLA-2002和NTLA-3001[6] 临床进展 - NTLA-2001在早期试验中显示出令人鼓舞的结果，显著减少了患者体内的疾病引起蛋白质[4] - 公司计划在今年开始NTLA-2001的第三阶段研究，与生物技术巨头Regeneron合作，大大降低了项目资金不足的风险[5] 财务状况 - 公司在2023年底拥有大约10亿美元现金，管理层认为这笔资金可以维持到2026年中期[8] 投资建议 - 投资者应该意识到Intellia Therapeutics目前是一个高风险、高回报的投资选择，只有那些能接受高波动性的投资者才应该考虑投资[9] - 如果公司能够展示出扎实的临床进展，未来几年可能会带来巨大的回报[10]

SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa Positive recommendation received from the Data Safety Monitoring Board (DSMB) enabling progression to highest dose of Part 1 of the PRODYGY trialFavorable safety and tolerability profiles observed with first two SPVN06 doses across six patients (three patients per cohort)Exploration of SPVN06 in geographic atrophy to begin in 2024 Paris, 24 January 2024 – SparingVision ("the Company"), a clinical-stage gen ...

One stock that might be an intriguing choice for investors right now is Intellia Therapeutics, Inc. (NTLA) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably t ...

公司介绍 - Intellia Therapeutics, Inc.（NASDAQ:NTLA）是一家领先的临床阶段基因编辑公司，专注于用CRISPR技术革新医学[2] 2023年计划 - 2023年对Intellia来说是具有里程碑意义的一年，NTLA-2001进入了治疗转甲状腺激素前体蛋白淀样变性伴心肌病的临床开发最后阶段[2] - 公司计划在2026年前完成NTLA-2002的第三阶段研究和BLA提交，以及NTLA-2001关键研究的患者招募[1]